GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PRNewswire 25-Feb-2025 12:00 PM

LOS ANGELES, Feb. 25, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against GSK plc. ("GSK" or the "Company") (NYSE: GSK).

IF YOU SUFFERED A LOSS ON YOUR GSK INVESTMENTS, CLICK HERE BEFORE APRIL 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?
The complaint filed alleges that, between February 5, 2020, and August 14, 2022, Defendants failed to disclose to investors that: (1) GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market; (2) while Defendants asserted that "data published prior to 2019 claims" failed to establish a link between Zantac and cancer, they failed to disclose that GSK possessed unpublished data – the Tanner Report – that did exactly that; (3) the representations about Defendants' ability to "quantify or reliably estimate the liability" deceived investors, who did not know that GSK had for decades concealed an internal study that implicated the Company's liability to Zantac users; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:
If you wish to?learn more?about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay & Murray LLP, 
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email: shareholders@glancylaw.com
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/gsk-plc-gsk-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302384704.html

SOURCE Glancy Prongay & Murray LLP